Based on the Assertio Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Assertio Therapeutics Inc is USD 3.31 over the next 12 months. Assertio Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Assertio Therapeutics Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, Assertio Therapeutics Inc’s stock price was USD 0.90. Assertio Therapeutics Inc’s stock price has changed by +6.76% over the past week, -8.07% over the past month and -21.74% over the last year.
No recent analyst target price found for Assertio Therapeutics Inc
No recent average analyst rating found for Assertio Therapeutics Inc
Company Overview Assertio Therapeutics Inc
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. Read Less
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute fl...Read More
Frequently Asked Questions About Assertio Therapeutics Inc (ASRT) Stock
Based on ratings from 4 analysts Assertio Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on ASRT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ASRT is USD 3.31 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 2.15.
ASRT stock's Price/Earning ratio is 1.20.
Our analysis grades ASRT stock's Price / Earning ratio at B-. This means that ASRT stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ASRT may be undervalued for its sector.
The last closing price of ASRT's stock was USD 0.90.
The most recent market capitalization for ASRT is USD 0.08B.
Based on targets from 4 analysts, the average taret price for ASRT is projected at USD 3.31 over the next 12 months.
This means that ASRT's stock price may go up by +267.46% over the next 12 months.
We can't find any ETFs which contains Assertio Therapeutics Inc's stock.
As per our most recent records Assertio Therapeutics Inc has 53 Employees.
Assertio Therapeutics Inc's registered address is 100 South Saunders Road, Lake Forest, IL, United States, 60045.
You can get more information about it from Assertio Therapeutics Inc's website at https://www.assertiotx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Assertio Therapeutics Inc (ASRT) Stock
Based on ratings from 4 analysts Assertio Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on ASRT's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ASRT is USD 3.31 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 2.15.
ASRT stock's Price/Earning ratio is 1.20.
Our analysis grades ASRT stock's Price / Earning ratio at B-. This means that ASRT stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this ASRT may be undervalued for its sector.
The last closing price of ASRT's stock was USD 0.90.
The most recent market capitalization for ASRT is USD 0.08B.
Based on targets from 4 analysts, the average taret price for ASRT is projected at USD 3.31 over the next 12 months.
This means that ASRT's stock price may go up by +267.46% over the next 12 months.
We can't find any ETFs which contains Assertio Therapeutics Inc's stock.
As per our most recent records Assertio Therapeutics Inc has 53 Employees.
Assertio Therapeutics Inc's registered address is 100 South Saunders Road, Lake Forest, IL, United States, 60045.
You can get more information about it from Assertio Therapeutics Inc's website at https://www.assertiotx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ASRT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
